Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Business Segments — D&A

Similar metrics at other companies

OLP
OLPXReportable Segment — D&A
$13.32M-0.4%
V2X logo
VVXReportable Segment — D&A
$28.11M+0.3%
Anterix logo
ATEXReportable Segment — D&A
$103K+35.5%
DocuSign logo
DOCUReportable Segment — D&A
$32.21M+6.1%
Chewy logo
CHWYReportable Segment — D&A
$37M+23.3%
CWA
CWANReportable Segment — D&A
$29.56M+840%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.56B+66.3%
Enterprise value$4.9B+88.3%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemThree Months Ended March 31, 20262025
Cash flows from operating activities:
Net income$89$47
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization23
Amortization of right-of-use assets22
Stock-based compensation expense96
Impairment of tangible and intangible assets6
Loss on debt extinguishment18

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s business segments — D&A?
Indivior Pharmaceuticals, Inc. (INDV) reported business segments — D&A of $2M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s business segments — D&A changed year-over-year?
Indivior Pharmaceuticals, Inc.'s business segments — D&A decreased by 33.3% year-over-year, from $3M to $2M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s business segments — D&A?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s business segments — D&A has grown at a -18.4% compound annual growth rate (CAGR), from $15M to $10M.
What does business segments — D&A mean?
This represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the reportable segment. Monitoring this helps investors understand the capital intensity and the ongoing reinvestment requirements of the segment's operations.

Ask your AI about Indivior Pharmaceuticals, Inc.'s business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude